AgingResearch.NewsJoin free

Senlect

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Australian Cancer Research Foundation and 3 more
  • Cells1

Outcomes

1

Senescence-related phenotypes

upin human cells1

1 study

  1. Senlect increases senescence-related phenotypes in human cells.

    “Puromycin-selected cells were enriched for various senescence-related phenotypes, including cell cycle arrest, increased cell size, and lysosomal β-galactosidase activity.”

    CellsSenLect-mediated puromycin selectionprimary HUVECs and HeLa cervical cancer cells

    SenLect: a genetically encoded system to purify senescent cells

    bioRxiv (Cold Spring Harbor Laboratory)15 Sep 2025Preprint

Latest

Related